Andrew J. Neville

Mr. Andrew J. Neville

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ANAndrew J. Neville
Andrew J. Neville
SZSydney J. Zach
Sydney J. Zach
XWXiaofang Wang
Xiaofang Wang
JLJoshua J. Larson
Joshua J. Larson
AJAbigail K. Judge
Abigail K. Judge
PDPaul H. Davis
Paul H. Davis
Toxoplasma gondiiis an apicomplexan parasite of humans and other mammals, including livestock and companion animals. While chemotherapeutic regimens, including pyrimethamine and sulfadiazine regimens, ameliorate acute or recrudescent disease such as toxoplasmic encephalitis or ocular toxoplasmosis, these drugs are often toxic to the host. Moreover, no approved options are available to treat infected women who are pregnant. Lastly, no drug regimen has shown the ability to eradicate the chronic stage of infection, which is characterized by chemoresistant intracellular cysts that persist for the life of the host. In an effort to promote additional chemotherapeutic options, we now evaluate clinically available drugs that have shown efficacy in disease models but which lack clinical case reports. Ideally, less-toxic treatments for the acute disease can be identified and developed, with an additional goal of cyst clearance from human and animal hosts.

1 December 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MMMadalyn M. McFarland
Madalyn M. McFarland
SZSydney J. Zach
Sydney J. Zach
XWXiaofang Wang
Xiaofang Wang
LPLakshmi-Prasad Potluri
Lakshmi-Prasad Potluri
ANAndrew J. Neville
Andrew J. Neville
PDPaul H. Davis
Paul H. Davis
Toxoplasma gondiiis a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options forT. gondiiinfection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition ofin vitrogrowth ofT. gondii. When available, host cell toxicity andin vivodata are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasmacompounds and potentially to extend our knowledge of the parasite.

24 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CDCarolina Beltrame Del Debbio
Carolina Beltrame Del Debbio
QMQulsum Mir
Qulsum Mir
SPSowmya Parameswaran
Sowmya Parameswaran
SMSaumi Mathews
Saumi Mathews
XXXiaohuan Xia
Xiaohuan Xia
IAIqbal Ahmad
Iqbal Ahmad
Müller glia (MG), the sole glial cells generated by retinal progenitors, have emerged as a viable cellular target for therapeutic regeneration in degenerative blinding diseases, as they possess dormant stem cell properties. However, the mammalian MG does not display the neurogenic potential of their lower vertebrate counterparts, precluding their practical clinical use. The answer to this barrier may be found in two interlinked processes underlying the neurogenic potential, i.e., the activation of the dormant stem cell properties of MG and their differentiation along the neuronal lineage. Here, we have focused on the former and examined Notch signaling-mediated activation of MG. We demonstrate that one of the targets of Notch signaling is the cyclin-dependent kinase inhibitor (CKI), p27Kip1, which is highly expressed in quiescent MG. Notch signaling facilitates the activation of MG by inhibiting p27Kip1 expression. This is likely achieved through the Notch- p27Kip1 and Notch-Skp2-p27Kip1 axes, the former inhibiting the expression of p27Kip1 transcripts and the latter levels of p27Kip1 proteins by Skp2-mediated proteasomal degradation. Thus, Notch signaling may facilitate re-entry of MG into the cell cycle by inhibiting p27Kip1 expression both transcriptionally and post-translationally.

18 October 2024 in ACS Infectious Diseases
Verified
Journal Article
Closed access
DLDerek A. Leas
Derek A. Leas
JKJennifer Keiser
Jennifer Keiser
SCSusan A. Charman
Susan A. Charman
DSDavid M. Shackleford
David M. Shackleford
JJJeremy O. Jones
Jeremy O. Jones
JVJonathan Vennerstrom
Jonathan Vennerstrom

16 March 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
CEClare F Euteneuer
Clare F Euteneuer
BDBrianna N Davis
Brianna N Davis
LLLeeAnna M. Lui
LeeAnna M. Lui
ANAndrew J. Neville
Andrew J. Neville
PDPaul H. Davis
Paul H. Davis
The rise of bacterial infections is a global health issue that calls for the development and availability of additional antimicrobial agents. Known for its in vitro effects on Gram-positive organisms, the drug-like small molecule marinopyrrole A was re-examined for the potential of broader efficacy against a wider array of microbes. We uncovered selective efficacy against an important subset of Gram-negative bacteria from three genera: Neisseria, Moraxella, and Campylobacter. This susceptibility is correlated with the absence of canonical LPS in these specific Gram-negative species, a phenomenon observed with other hydrophobic anti-microbial compounds. Further, when exposed to molecules which inhibit the LpxC enzyme of the LPS synthesis pathway, previously resistant LPS-producing Gram-negative bacteria showed increased susceptibility to marinopyrrole A. These results demonstrate marinopyrrole A’s efficacy against a broader range of Gram-negative bacteria than previously known, including N. gonorrhea, a species identified as a priority pathogen by the WHO.

18 July 2024 in Microbiology Resource Announcements
Verified
Journal Article
Open access
TSThomas T. Schulze
Thomas T. Schulze
ANAndrew J. Neville
Andrew J. Neville
GWGabrielle F. Watson
Gabrielle F. Watson
ASAustin G. Sanford
Austin G. Sanford
HWHarim I. Won
Harim I. Won
WTWilliam E. Tapprich
William E. Tapprich
We provide the complete genome sequence for a novel Pseudomonas fluorescens bacteriophage named UNO-G1W1. This phage was isolated from a single ice cover sampling. The genome was sequenced on the Nanopore MinION, generated with the direct terminal repeat-phage-pipeline and polished with Illumina short reads. Sequence identity classifies the phage as an otagovirus .